Table 1

Baseline characteristics of study population stratified by study group

RLC (n=113)NLC (n=111)Total (224)
Women, n (%)86 (76.8)80 (72.1)166 (74.4)
Age (years), mean (SD)58.10 (11.54)58.81 (12.03)58.57 (11.88)
RF-positive (n)105101206
ACPA-positve (n)9696192
Employed, n (%) (112, 110)*51 (45.5)54 (49.1)105 (47.3)
Education (92, 94)*
 No secondary school, n (%)89 (96.7)83 (88.3)172 (77.10)
 Secondary school, n (%)3 (3.3)11 (11.7)14 (6.30)
Professional training (111,109)*
 None, n (%)18 (16.2)16 (14.7)34 (15.2)
 Vocational, n (%)85 (76.6)79 (72.41)164 (73.5)
 University degree, n (%)8 (7.2)14 (12.8)22 (9.9)
Therapy regimen
 New therapy, n (%)41 (36.6)28 (25.2)69 (30.9)
 Change of therapy, n (%)40 (35.7)49 (44.1)89 (39.9)
 Dose escalation, n (%)31 (27.7)34 (30.6)65 (29.1)
Disease duration (years), median (IQR) (111, 109)5.83 (2.5–13)7.67 (2.63–18.79)6.24 (2.6–26.19)
Baseline RA regimen, n (%)
 Glucocorticoids (103,104)*39 (37.8)39 (37.5)78 (37.7)
 Methotrexate (103, 105)35 (34.0)41 (39.0)76 (36.5)
 Leflunomide (103, 104)*14 (13.6)11 (10.6)25 (12.1)
 Sulfasalazine (103, 104)*4 (3.9)4 (3.8)8 (3.9)
 Hydroxychloroquine (103, 104)*4 (3.9)2 (1.9)6 (2.9)
 JAK inhibitors2 (1.8)0 (0)2 (0.9)
 Biological DMARD22 (21.4)27 (25.9)49 (21.97)
Outcomes, median (IQR)
 DAS28-CRP (110, 111)4.41 (3.48–5.07)4.51 (3.42–5.18)4.42 (3.48–5.16)
 Tender joints6 (2–10)6 (2–12)6 (2–11)
 Swollen joints3 (1–6)3 (1–6)3 (1–6)
 Patient Global Health60 (43.5–74.75)60 (40–79)60 (42–75)
 FFbH (111, 109)*77.78 (61.11–88.89)75 (52.78–88.89)77.78 (56.25–88.89)
 RADAI (110, 110)*4.75 (3.14–5.82)4.70 (3.36–6.10)4.73 (3.23–5.99)
 RAID total (112,110)*5.30 (3.67–6.90)5.32 (2.84–7.21)5.30 (3.34–7.07)
 Pain (112, 110)*6 (4–8)6 (4–8)6 (4–8)
 Fatigue (112, 110)*5 (3–7)5 (3–8)5 (3–8)
HADS (112, 109)*
 Depression6 (3–9)4 (2–8)5 (2–8)
 Anxiety6 (3–9)6 (3–10)6 (3–9)
ZAP
 Trust (112, 110)4 (3–4)4 (4–4)4 (3–4)
 Quality (110, 109)2 (2–3)3 (2–3)3 (2–3)
 Satisfaction (110, 109)2 (2–3)3 (2–3)3 (2–3)
  • *Numbers of available data were as per randomised allocation, that is, 113 for RLC and 111 for NLC unless otherwise stated in parentheses.

  • ACPA, anticitrullinated protein antibody; DAS28-CRP, Disease Activity Score in 28 Joints measured with C reactive protein; DMARD, disease-modifying antirheumatic drug; FFbH, Funktionsfragebogen Hannover; HADS, Hospital Anxiety and Depression Scale; NLC, nurse-led care; RA, rheumatoid arthritis; RADAI, Rheumatoid Arthritis Disease Activity Index; RAID, Rheumatoid Arthritis Impact of Disease; RF, rheumatoid factor; RLC, rheumatologist-led care; ZAP, 'Fragebogen zur Zufriedenheit in der ambulanten Versorgung', satisfaction about outpatient care.